SAB Biotherapeutics Inc.

12/01/2021 | Press release | Distributed by Public on 12/01/2021 06:05

SAB Biotherapeutics Announces SAB-176 Met its Primary Endpoint in Phase 2a Challenge Study in Adults Infected with Influenza Virus